Abstract Technologies that enable thermal therapy treatments are now clinically viable and most ongoing hyperthermia clinical trials in oncology incorporate chemotherapy. Given the extensive list of chemotherapies that are enhanced by hyperthermia and the ability of thermosensitive nanomedicines to deliver increased amounts of drug to tumors, while not relying on the EPR effect, there is real opportunity for the clinical translation of thermosensitive nanomedicines. To realize this potential, improved thermosensitive nanomedicines encapsulating a wider range of drugs must be developed and advanced into clinical trials.

中文翻译：

---

热敏纳米药物可以彻底改变肿瘤学中的热疗法

摘要 使热疗治疗成为可能的技术现在在临床上是可行的，并且大多数正在进行的肿瘤学热疗临床试验都结合了化疗。鉴于通过热疗增强的化学疗法种类繁多，以及热敏纳米药物向肿瘤输送更多药物的能力，同时不依赖于 EPR 效应，热敏纳米药物的临床转化有真正的机会。为了实现这一潜力，必须开发封装更广泛药物的改良热敏纳米药物并推进临床试验。